U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C24H29N5O3
Molecular Weight 435.5197
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of VALSARTAN

SMILES

CCCCC(=O)N(Cc1ccc(cc1)-c2ccccc2-c3n[nH]nn3)[C@@]([H])(C(C)C)C(=O)O

InChI

InChIKey=ACWBQPMHZXGDFX-QFIPXVFZSA-N
InChI=1S/C24H29N5O3/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H,31,32)(H,25,26,27,28)/t22-/m0/s1

HIDE SMILES / InChI
Molecular Formula C24H29N5O3
Molecular Weight 435.5197
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment:: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/2009869

There is no information in the literature about pharmacological and biological application of definite isomer of valsatran, R – form (also known as VALSARTAN, D- or CGP-49309). However there were found, that in the tablets of valsartan, which are used to treat high blood pressure and to heart failure, the R-enantiomer was an impurity.

CNS Activity

CNS Active
1726
Curator's Comment:: LBQ657 (an LCZ696 metabolite) achieves CSF concentrations sufficient to inhibit neprilysin, but LCZ696 did not cause changes in CSF levels of aggregable Abeta isoforms (1-42 and 1-40) compared with placebo

Originator

Approval Year

1996
89
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
1131
 2.38 nM [Ki]
Inhibitor
3315
 2.3 nM [IC50]
Blocker
231
 2.43 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
4033
ENTRESTO

Approved Use

ENTRESTO is a combination of sacubitril, a neprilysin inhibitor, and valsartan, an angiotensin II receptor blocker, indicated to reduce the risk of cardiovascular death and hospitalization for heart failure in patients with chronic heart failure (NYHA Class II-IV) and reduced ejection fraction. ENTRESTO is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.

Launch Date

1.43614083E12
Primary
Approved
4033
DIOVAN

Approved Use

Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)

Launch Date

1.31086077E12
Primary
Approved
4033
DIOVAN

Approved Use

Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)

Launch Date

1.31086077E12
Palliative
Approved
4033
DIOVAN

Approved Use

Diovan is an angiotensin II receptor blocker (ARB) indicated for: Treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions (1.1) Treatment of heart failure (NYHA class II-IV); Diovan significantly reduced hospitalization for heart failure (1.2) Reduction of cardiovascular mortality in clinically stable patients with left ventricular failure or left ventricular dysfunction following myocardial infarction (1.3)

Launch Date

1.31086077E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
2808 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
5756 ng/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
2.141 μg/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21617777
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
20650 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
34310 ng × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
22.56 μg × h/mL
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21617777
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
8.45 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
8 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/27128457
80 mg single, oral
dose: 80 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
9.55 h
EXPERIMENT
https://pubmed.ncbi.nlm.nih.gov/21617777
160 mg single, oral
dose: 160 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VALSARTAN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
2.24 mg single, oral
Overdose
Dose: 2.24 mg
Route: oral
Route: single
Dose: 2.24 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
Other AEs: Muscle cramps...
Other AEs:
Muscle cramps (1 patient)
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Disc. AE: Hyperkalemia...
Other AEs: Dizziness, Headache...
AEs leading to
discontinuation/dose reduction:
Hyperkalemia (1 patient)
Other AEs:
Dizziness (8.3%)
Headache (9.2%)
Back pain (5.8%)
Upper respiratory tract infection (5.8%)
Nasopharyngitis (5%)
Diarrhea (5%)
Hypoglycemia (5%)
Peripheral edema (4.2%)
Nausea (4.2%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
pregnant
Health Status: pregnant
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
Disc. AE: Disorder fetal...
AEs leading to
discontinuation/dose reduction:
Disorder fetal
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2316
Health Status: unhealthy
Condition: hypertension
Population Size: 2316
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Disc. AE: Headache, Dizziness...
AEs leading to
discontinuation/dose reduction:
Headache (2.3%)
Dizziness (2.3%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2506
Health Status: unhealthy
Condition: Heart Failure
Population Size: 2506
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Disc. AE: Creatinine increased, Potassium increased...
AEs leading to
discontinuation/dose reduction:
Creatinine increased (0.5%)
Potassium increased (0.5%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Muscle cramps 1 patient
2.24 mg single, oral
Overdose
Dose: 2.24 mg
Route: oral
Route: single
Dose: 2.24 mg
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
unknown, 25 years
n = 1
Health Status: unknown
Age Group: 25 years
Sex: F
Population Size: 1
Sources:
https://pubmed.ncbi.nlm.nih.gov/15222725
Hyperkalemia 1 patient
Disc. AE
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Nausea 4.2%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Peripheral edema 4.2%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Diarrhea 5%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Hypoglycemia 5%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Nasopharyngitis 5%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Back pain 5.8%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Upper respiratory tract infection 5.8%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Dizziness 8.3%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Headache 9.2%
640 mg 1 times / day steady, oral
Highest studied dose
Dose: 640 mg, 1 times / day
Route: oral
Route: steady
Dose: 640 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
unhealthy, 57.5 years
n = 131
Health Status: unhealthy
Age Group: 57.5 years
Sex: M+F
Population Size: 131
Sources:
https://pubmed.ncbi.nlm.nih.gov/17762658
Disorder fetal Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
pregnant
Health Status: pregnant
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
https://pubmed.ncbi.nlm.nih.gov/15329835
Dizziness 2.3%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2316
Health Status: unhealthy
Condition: hypertension
Population Size: 2316
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Headache 2.3%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2316
Health Status: unhealthy
Condition: hypertension
Population Size: 2316
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Creatinine increased 0.5%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2506
Health Status: unhealthy
Condition: Heart Failure
Population Size: 2506
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Potassium increased 0.5%
Disc. AE
320 mg 1 times / day steady, oral
Recommended
Dose: 320 mg, 1 times / day
Route: oral
Route: steady
Dose: 320 mg, 1 times / day
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
unhealthy
n = 2506
Health Status: unhealthy
Condition: Heart Failure
Population Size: 2506
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020665s039lbl.pdf
Sourcing

Sourcing

Vendor/AggregatorIDURL
ChEBI
CHEBI:9927
https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:9927
ChemicalBook
CB14657818
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB14657818
ChemicalBook
CB23133442
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB23133442
ChemicalBook
CB34813436
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB34813436
ChemicalBook
CB3952405
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB3952405
ChemicalBook
CB6182539
https://www.chemicalbook.com/ChemicalProductProperty_EN_CB6182539
MolPort
MolPort-002-507-854
https://www.molport.com/shop/molecule-link/MolPort-002-507-854
MolPort
MolPort-003-666-608
https://www.molport.com/shop/molecule-link/MolPort-003-666-608
Selleck Chemicals
Valsartan(Diovan)
http://www.selleckchem.com/products/Valsartan(Diovan).html
ZINC
ZINC000003875259
http://zinc15.docking.org/substances/ZINC000003875259
eMolecules
1989469
https://www.emolecules.com/cgi-bin/more?vid=1989469
eMolecules
2724803
https://www.emolecules.com/cgi-bin/more?vid=2724803
eMolecules
32278148
https://www.emolecules.com/cgi-bin/more?vid=32278148
eMolecules
33507560
https://www.emolecules.com/cgi-bin/more?vid=33507560
PubMed

PubMed

TitleDatePubMed
Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype.
1993 Oct
Angiotensin II receptor blockade with single doses of valsartan in healthy, normotensive subjects.
1994
Binding of valsartan to mammalian angiotensin AT1 receptors.
1995 Nov 10
Remodelling of resistance arteries in genetically hypertensive rats by treatment with valsartan, an angiotensin II receptor antagonist.
1996 Jun-Jul
Development and validation of chiral high-performance liquid chromatographic methods for the quantitation of valsartan and of the tosylate of valinebenzyl ester.
1996 Nov 8
Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine.
1996 Sep
Enantiomeric LC separation of valsartan on amylose based stationary phase.
2009 Aug
Efficacy and safety of LCZ696, a first-in-class angiotensin receptor neprilysin inhibitor, in Asian patients with hypertension: a randomized, double-blind, placebo-controlled study.
2014 Apr
Determination of the R-enantiomer of valsartan in pharmaceutical formulation by capillary electrophoresis.
2015
LCZ696 : a new paradigm for the treatment of heart failure?
2015 Feb
Sacubitril/valsartan (LCZ696) for the treatment of heart failure.
2016
LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice.
2016 Apr
Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction.
2016 Aug
LCZ696 (Valsartan/Sacubitril)--A Possible New Treatment for Hypertension and Heart Failure.
2016 Jan
Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
2016 Mar
Patents

Patents

US20050010053
1
US5399578
1
US5965592
1
US6294197
1
US8475839
1
WO/2016/151525A1
1
null
3

Sample Use Guides

In Vivo Use Guide
The recommended starting dose of ENTRESTO, previously known as LCZ696, is 49/51 mg (sacubitril/valsartan) twice-daily. Double the dose of ENTRESTO after 2 to 4 weeks to the target maintenance dose of 97/103 mg (sacubitril/valsartan) twice-daily, as tolerated by the patient.
Route of Administration: Oral
In Vitro Use Guide
Sources: Von Lueder TG, Wang B, Kompa A, Huang L, Webb R, Jordan P, Krum H. ARNi, combined neprilysin and angiotensin receptor inhibition augments anti-fibrotic and anti-hypertrophic effects in vitro. Eur.Heart J. 2012;33:P5834.
Curator's Comment:: ...
30 nM to 1 uM valsartan (LCZ696 component) in the presence of 10 uM LBQ657 (Sacubitril (LCZ696 component) metabolite) demonstrate anti-fibrotic and anti-hypertrophic effects on rat cardiac fibroblasts and cardiomyocytes, respectively, cultured with 100 nM angiotensin II
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:21 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:21 UTC 2021
Record UNII
80M03YXJ7I
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VALSARTAN
EMA EPAR   EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
INN   USAN  
Official Name English
VALSARTAN COMPONENT OF COPALIA
Brand Name English
COPALIA COMPONENT VALSARTAN
Brand Name English
VALSARTAN COMPONENT OF VALTURNA
Common Name English
L-VALINE, N-(1-OXOPENTYL)-N-((2'-(1H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-
Systematic Name English
VALSARTAN [VANDF]
Common Name English
VALSARTAN COMPONENT OF EXFORGE HCT
Common Name English
BYVALSON COMPONENT OF VALSARTAN
Common Name English
IMPRIDA-HCT COMPONENT VALSARTAN
Brand Name English
NSC-758927
Code English
CGP 48933
Code English
DIOVAN HCT COMPONENT VALSARTAN
Common Name English
VALSARTAN [EMA EPAR]
Common Name English
VALSARTAN [MI]
Common Name English
VALSARTAN [USP MONOGRAPH]
Common Name English
VALTURNA COMPONENT VALSARTAN
Brand Name English
VALSARTAN [USAN]
Common Name English
VALSARTAN [ORANGE BOOK]
Common Name English
VALSARTAN [MART.]
Common Name English
VALSARTAN COMPONENT OF IMMPRIDA
Brand Name English
VALSARTAN COMPONENT OF DIOVAN HCT
Common Name English
EXFORGE COMPONENT VALSARTAN
Brand Name English
VALSARTAN COMPONENT OF EXFORGE
Brand Name English
DIOVAN
Brand Name English
VALSARTAN [EP]
Common Name English
DAFIRO COMPONENT VALSARTAN
Brand Name English
VALSARTAN [HSDB]
Common Name English
VALSARTAN COMPONENT OF ENTRESTO
Brand Name English
COPALIA-HCT COMPONENT VALSARTAN
Brand Name English
EXFORGE HCT COMPONENT VALSARTAN
Common Name English
VALSARTAN [USP-RS]
Common Name English
VALSARTAN [JAN]
Common Name English
VALSARTAN [WHO-DD]
Common Name English
VALSARTAN COMPONENT OF DAFIRO-HCT
Brand Name English
VALSARTAN COMPONENT OF COPALIA-HCT
Brand Name English
VALSARTAN COMPONENT OF BYVALSON
Common Name English
ENTRESTO COMPONENT VALSARTAN
Brand Name English
VALSARTAN [EP MONOGRAPH]
Common Name English
PREXXARTAN
Brand Name English
IMPRIDA COMPONENT VALSARTAN
Brand Name English
VALSARTAN [INN]
Common Name English
VALSARTAN COMPONENT OF IMPRIDA-HCT
Brand Name English
DAFIRO-HCT COMPONENT VALSARTAN
Brand Name English
N-(P-(O-1H-TETRAZOL-5-YLPHENYL)BENZYL)-N-VALERYL-L-VALINE
Common Name English
CGP-48933
Code English
Classification Tree Code System Code
WHO-ATC C09CA03
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS IMPRADA-HCT (WITHDRAWN: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C10BX10
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS EXFORGE (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-VATC QC09CA03
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
NDF-RT N0000175561
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C09DX02
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS COPALIA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C09DX01
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-VATC QC09DA03
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS EXFORGE-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
NCI_THESAURUS C66930
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C09DB08
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS DARFIRO-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
LIVERTOX 1019
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS COPALIA-HCT (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C09DA03
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
NDF-RT N0000000070
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS DAFIRO (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
FDA ORPHAN DRUG 494115
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-VATC QC09DX01
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
EMA ASSESSMENT REPORTS IMPRIDA (AUTHORIZED: HYPERTENSION)
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C09DX05
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C09DX04
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-VATC QC09DX02
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-ATC C09DB01
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
WHO-VATC QC09DB01
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
Code System Code Type Description
INN
7016
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
RXCUI
69749
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY RxNorm
CAS
137862-53-4
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
IUPHAR
3937
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
ChEMBL
CHEMBL1069
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
FDA UNII
80M03YXJ7I
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
MESH
C081489
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
WIKIPEDIA
VALSARTAN
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
USP_CATALOG
1708762
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY USP-RS
HSDB
7519
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
EPA CompTox
137862-53-4
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
DRUG BANK
DB00177
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
NCI_THESAURUS
C47781
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
LACTMED
Valsartan
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
DRUG CENTRAL
2806
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
MERCK INDEX
M11372
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY Merck Index
PUBCHEM
60846
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
EVMPD
SUB00017MIG
Created by admin on Fri Jun 25 21:02:22 UTC 2021 , Edited by admin on Fri Jun 25 21:02:22 UTC 2021
PRIMARY
Related Record Type Details
OATP1B1
TRANSPORTER -> INHIBITOR
PEPT-1
TRANSPORTER -> INHIBITOR
TYPE-1 ANGIOTENSIN II RECEPTOR
TARGET -> INHIBITOR
OAT-4
TRANSPORTER -> INHIBITOR
Structure of SACUBITRIL VALSARTAN SODIUM HYDRATE
SALT/SOLVATE -> PARENT
OAT-3
TRANSPORTER -> INHIBITOR
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
Structure of VALSARTAN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
Structure of VALSARTAN
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
PEPT-2
TRANSPORTER -> INHIBITOR
OAT-1
TRANSPORTER -> INHIBITOR
Related Record Type Details
Structure of VALERYL-4-HYDROXYVALSARTAN
METABOLITE INACTIVE -> PARENT
Structure of VALERYL-4-HYDROXYVALSARTAN
METABOLITE INACTIVE -> PARENT
Valsartan was metabolized to a small extent only. The only notable metabolite in plasma, urine and faecs
MAJOR
FECAL; PLASMA; URINE
Related Record Type Details
Structure of VALSARTAN BENZYL ESTER
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-(1-OXOPENTYL)-N-((2'-(2H-TETRAZOL-5-YL)(1,1'-BIPHENYL)-4-YL)METHYL)-L-VALINE METHYL ESTER
IMPURITY -> PARENT
Structure of N-NITROSODIETHYLAMINE
IMPURITY -> PARENT
Probable human carcinogen.
Structure of VALSARTAN BENZYL ESTER
IMPURITY -> PARENT
UNSPECIFIED
EP
Structure of VALSARTAN, D-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of BENZYL(METHYL)NITROSAMINE
IMPURITY -> PARENT
Priority toxic pollutant.
Structure of DESPENTANOYL BUTANOYL VALSARTAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DESPENTANOYL BUTANOYL VALSARTAN
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of METHYL N-((2'-CYANO(1,1'-BIPHENYL)-4-YL)METHYL)-L-VALINATE
IMPURITY -> PARENT
Structure of VALSARTAN, D-
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of N-NITROSODIMETHYLAMINE
IMPURITY -> PARENT
NDMA is an organic chemical that is in a family of potent carcinogens.
Related Record Type Details
Structure of VALSARTAN
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

MAXIMUM TOLERATED DOSE TOXICITY
PROTEIN BINDING PHARMACOKINETIC
Route of Elimination PHARMACOKINETIC ROUTE OF ADMINISTRATION: ORAL

RENAL CLEARANCE PHARMACOKINETIC
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966